Komori
Daito Pharmaceutical (4577) · InitiativeAdvanced

Assessment of Climate Change Risks and Opportunities and Response Based on the TCFD Recommendations

First written in FY2022. 4 of 5 entries say "Advanced", first in FY2023. Latest entry: FY2026.

5entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022AdvancedFY2023 – FY20262022: 120222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies
TCFD-Based Climate Change Scenario Analysis and DisclosureA theme 563 companies write about · 117 as a headwind · 331 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 195 companies compared. The sentences above are computed from all 195.Comparing 200 of the theme's 579 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「GHG emissions for the fiscal year ended May 2026: Scope 1 emissions (consolidated): 9,611 t-CO2 Scope 2 emissions (consolidated): 16,792 t-CO2 Scope 3 emissions (ダイト standalone): 152,025 t-CO2 (including the Shimo-Okui Plant) The long-term GHG reduction targets were set as follows, with reference to SBT indicators and other benchmarks and using fiscal 2023 as the base year. Scope 1 + 2: 25% reduction from the base year (fiscal 2023); aim for net-zero emissions Scope 3: To be determined; aim for net-zero emissions For the time being, the Company plans to reduce emissions, primarily Scope 2, by purchasing renewable energy and assess progress annually. For Scope 3, it plans to set reduction targets by 2027 while improving the accuracy of its calculations.」

    The Company updated its actual GHG emissions through the fiscal year ended May 2026 and specified its policy of reducing Scope 2 emissions through renewable energy purchases, assessing progress annually and setting Scope 3 reduction targets by 2027.
  2. FY2025AdvancedAnnual report

    「The long-term GHG reduction targets were set as follows, with reference to SBT indicators and other benchmarks and using fiscal 2023 as the base year. Scope 1 + 2 25% reduction from the base year (fiscal 2023) Aim for net-zero emissions Scope 3 To be determined Aim for net-zero emissions」

    The Company set targets for the first time to reduce Scope 1 and 2 emissions by 25% in fiscal 2030 and achieve net-zero emissions in fiscal 2050, and stated its policy of aiming for net-zero Scope 3 emissions in fiscal 2050. It also disclosed actual Scope 1, 2 and 3 emissions for the fiscal year ended May 2025.
  3. FY2024AdvancedAnnual report

    「Actual GHG emissions for the fiscal year ended May 2024 were as follows. Scope 1 emissions (consolidated): 9,102 t-CO2; Scope 2 emissions (consolidated): 19,303 t-CO2; Scope 3 emissions (ダイト standalone): 145,454 t-CO2. Going forward, the Company plans to set long-term GHG reduction targets and assess progress annually. It also plans to improve the calculation of Scope 3 emissions.」

    Regarding its response to the TCFD recommendations, the Company has disclosed quantitative assessments of financial impacts under multiple scenarios and actual Scope 1, 2 and 3 emissions, and has identified the setting of long-term reduction targets and annual progress assessments as future measures.
  4. FY2023AdvancedAnnual report

    「For the fiscal year ended May 2023, as the next step, we determined the “scenario set” and conducted a “quantitative assessment of financial impacts.” ◇ 1.5°C scenario: A world in which the transition to a decarbonised society progresses and the increase in average temperatures is limited to 1.5°C. ◇ 4°C scenario: A world in which the transition to a decarbonised society does not progress and average temperatures rise by 4°C or more.」

    Building on the establishment of the working group and start of scenario analysis in December 2021, the Company determined 1.5°C and 4°C scenarios for the fiscal year ended May 2023 and conducted a quantitative assessment of the financial impacts of climate-related risks and opportunities. Going forward, it plans to develop response measures and enhance information disclosure.
  5. FY2022First statedAnnual report

    「Our Group also strongly recognises the importance of understanding, from a long-term perspective, the risks and opportunities arising from climate change and their impact on our businesses, and taking measures such as reducing adverse impacts. We established a working group in December 2021 and began scenario analysis in line with the TCFD framework. From fiscal 2022 onward, we will advance quantitative assessments of financial impacts and the development of specific response measures, while strengthening our initiatives and enhancing information disclosure.」

    The Company established a TCFD response working group in December 2021 and began climate scenario analysis. From fiscal 2022 onward, it has disclosed for the first time its policy of advancing quantitative assessments of financial impacts, developing response measures and enhancing information disclosure.
Moved together

"Expected Expansion of the Generic Drug Market" moved the same way as this thread, in the same document, in 4 of its 5 moves.

443333★123456
  1. ★This thread
  2. 1Expected Expansion of the Generic Drug Market4×
  3. 2Expansion and Rationalization of Production and R&D Facilities4×
  4. 3Acquisition and retirement of treasury shares3×
  5. 4Restructuring the Group's production system and strengthening coordination3×
  6. 5Stable operation of the Chinese drug product manufacturing plant3×
  7. 6Recruitment and development of talent in overseas markets and high-potency pharmaceuticals3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Assessment of Climate Change Risks and Opportunities and Response Based on the TCFD Recommendations | Daito Pharmaceutical Co.,Ltd. (4577) | Komori